SAB Biotherapeutics SABSW Stock
SAB Biotherapeutics Price Chart
SAB Biotherapeutics SABSW Financial and Trading Overview
| SAB Biotherapeutics stock price | 0.01 USD |
| Previous Close | 0.02 USD |
| Open | 0.05 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.01 - 0.02 USD |
| 52 Week Range | 0.01 - 0.02 USD |
| Volume | 66.29K USD |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 0.058219183 |
| EPS (TTM) | 0.29 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
SABSW Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | 0.058219183 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.005666667 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
SAB Biotherapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | N/A |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.02 USD |
| 52 Week Low | 0.01 USD |
| 50-Day Moving Average | N/A |
| 200-Day Moving Average | N/A |
SABSW Share Statistics
| Avg. Volume (3 month) | N/A |
| Avg. Daily Volume (10-Days) | N/A |
| Shares Outstanding | N/A |
| Float | 52.34M |
| Short Ratio | N/A |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | N/A |
| Most Recent Quarter (mrq) | N/A |
| Next Fiscal Year End | N/A |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.37% |
| Return on Equity (ttm) | -0.32% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -33352332 USD |
| EBITDA | -55123040 USD |
| Net Income Avi to Common (ttm) | -9410830 USD |
| Diluted EPS (ttm) | 0.292 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 107.39M USD |
| Total Cash Per Share (mrq) | 1.4 USD |
| Total Debt (mrq) | 6.17M USD |
| Total Debt/Equity (mrq) | 2.72 USD |
| Current Ratio (mrq) | 11.447 |
| Book Value Per Share (mrq) | 3 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -51249024 USD |
| Levered Free Cash Flow (ttm) | -31485468 USD |
Profile of SAB Biotherapeutics
| Country | United States |
| State | FL |
| City | Miami Beach |
| Address | 777 W 41st St. |
| ZIP | 33140 |
| Phone | 305 845 2813 |
| Website | https://www.sab.bio |
| Industry | |
| Sector(s) | |
| Full Time Employees | 86 |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Q&A For SAB Biotherapeutics Stock
What is a current SABSW stock price?
SAB Biotherapeutics SABSW stock price today per share is 0.01 USD.
How to purchase SAB Biotherapeutics stock?
You can buy SABSW shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for SAB Biotherapeutics?
The stock symbol or ticker of SAB Biotherapeutics is SABSW.
How many shares does SAB Biotherapeutics have in circulation?
The max supply of SAB Biotherapeutics shares is 0.
What is SAB Biotherapeutics Price to Earnings Ratio (PE Ratio)?
SAB Biotherapeutics PE Ratio is 0.04863014 now.
What was SAB Biotherapeutics earnings per share over the trailing 12 months (TTM)?
SAB Biotherapeutics EPS is 0.29 USD over the trailing 12 months.